CLYM: Heavy Short Interest Meets Bullish Street Ahead of November Earnings

Climb Bio heads into its November 6 earnings date with a notable disconnect: 14 analysts are uniformly bullish, short sellers hold a significant position at nearly 14% of the free float, and the stock has lost 28% in a month while the options market turns sharply toward calls.

Short interest tells the central story this week. Bears hold 9.5 million shares short, equal to 14% of the free float, a level that has climbed 29% over the past month even as it pulled back 5.4% this week from a mid-October peak near 10.1 million shares. The ORTEX short score sits at 75.7, ranking in the bottom 6th percentile of all stocks on that metric, flagging this as one of the more heavily shorted names in the universe. Despite the size of the short position, the borrow market is not under pressure. Cost to borrow has drifted to 0.58%, near the bottom of its recent range, and availability is running at 77.6%, meaning roughly three shares are available for every four already lent out. That is well off the tightest point of the past 52 weeks, when availability fell to 11.4%. There is no meaningful squeeze pressure in the lending market right now, even with a high headline short number.

Options positioning flips that picture toward the optimistic side. Call demand has surged relative to recent norms: the put/call ratio has dropped to 0.23, nearly 1.7 standard deviations below its 20-day average of 0.53. That is a sharp reversal from mid-October, when the ratio was running around 0.63, and from September, when it briefly touched 1.28. Traders are loading up on calls, not hedging with puts, as the November 6 print approaches.

The Street backs that constructive tilt without a single dissenting voice. All 14 analysts covering CLYM rate it a Buy or equivalent, with a consensus price target of $27.60 against a close of $10.19. Deutsche Bank initiated coverage on October 20 with a Buy and a $28 target, the most recent action and a meaningful addition to an already unanimous panel. Earlier in the cycle, BTIG raised its target from $20 to $32 and HC Wainwright moved to $30, both responding to Phase 1 data on CLYM116 in September. The bull case centers on CLYM116's anti-APRIL profile: dose-proportional exposure, no target-mediated drug disposition, clean safety through 46 healthy volunteers, and a quarterly dosing thesis that could prove competitively differentiated. The bear case is equally clear: both CLYM116 and budoprutug remain in early development with no controlled efficacy data, and a Phase 3 start in pMN could force a dilutive equity raise before the cash runway ends in 2H28.

The ownership register adds a layer of complexity. RA Capital Management holds 21.8% of shares as last reported and has filed a Schedule 13D, making it an activist holder on the SEC register. FMR (Fidelity) added a near-complete new position to reach 11.8% of shares in the period ending September 30. BlackRock added 1.95 million shares to reach just over 4%. That institutional support is a counterweight to the bear position, though a separate 13D/A from AI ETI LLC was filed in late 2025 and subsequently showed a previous stake of 5.66% with no current percentage disclosed, consistent with that holder having exited. Stakes are as last disclosed around the 5% threshold, and any holder can fall below 5% without a further filing. On the insider side, the net 90-day picture is a disposal of 100,000 shares worth roughly $1.4 million, all from a director under a pre-arranged 10b5-1 plan. Planned sales carry less conviction signal than discretionary ones, and no open-market purchases appear in the recent record.

Earnings history on CLYM is volatile and skewed to the upside. The two most recent prints produced next-day moves of plus 13.5% and plus 12.3%. The print before that was a 1.3% decline, and the one before that a 6.9% decline. A binary pattern in a clinical-stage biotech is expected, and the NAVIGATE-2 data timeline for 1H27 means the November print is more likely to be a financial housekeeping event than a catalyst on its own, unless clinical updates accompany the release.

What to watch: whether the sharp drop in the put/call ratio into the print reflects genuine call buying on clinical optimism or simply thin liquidity in a low-float name, and whether short interest continues to retreat from its mid-October peak or rebuilds ahead of the November 6 date.